Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca says it's withdrawing COVID vaccine amid low demand - National globalnews.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalnews.ca Daily Mail and Mail on Sunday newspapers.
On Monday, 925 stocks advanced, 3039 declined and 118 remained unchanged, with an advance decline ratio of 0.30 on the Bombay Stock Exchange (BSE), indicating negative closing of stocks in broader markets.
Acurx Pharmaceuticals (ACXP) Granted FDA End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection As anticipated, an End of Phase 2.